STUDY PROTOCOL article
Front. Neurol.
Sec. Neurorehabilitation
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1653900
Efficacy Evaluation and Mechanistic Investigation of Transcutaneous Auricular Vagus Nerve Stimulation in Enhancing the Therapeutic Effects of Semaglutide and Reducing Its Gastrointestinal Side Effects: A Randomized Controlled Trial Protocol
Provisionally accepted
- 1Shandong University of Traditional Chinese Medicine School of Acupuncture and Tuina, Jinan, China
- 2China Academy of Chinese Medical Sciences, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background Type 2 diabetes mellitus(T2DM) is a chronic disorder with serious complications. Semaglutide, a GLP-1 receptor agonist, improves glycemic control and weight but is limited by gastrointestinal(GI) side effects, notably nausea, vomiting, and diarrhea, which impair adherence. Transcutaneous auricular vagus nerve stimulation (taVNS), a non-invasive therapy, shows potential in alleviating gastrointestinal symptoms, yet its role in mitigating semaglutide-related side effects and enhancing drug efficacy remains unexplored. Methods A total of 60 T2DM participants experiencing semaglutide-induced GI side effects will be randomly assigned to a control or intervention group. The control group will receive semaglutide (0.25 mg weekly) plus sham-taVNS, with electrodes attached to the bilateral auricular scapha at 4/20 Hz for 30 minutes, twice daily. The intervention group will receive semaglutide plus active taVNS, with electrodes on the bilateral cymba and cavum conchae using the same stimulation parameters. Treatment will span two 6-week cycles (12 weeks total). The primary outcome is the Rhodes Index of Nausea, Vomiting, and Retching. Secondary outcomes include gastric electromyography, serological markers, Visual Analogue Scale, and the Simplified Nutritional Appetite Questionnaire. Adverse events will be monitored, and assessments will occur at baseline, week 6, end of treatment, and follow-up. Discussion This study aims to determine whether taVNS can alleviate semaglutide-induced GI side effects and enhance the therapeutic efficacy of semaglutide. Conclusion This study protocol has a randomized, sham-controlled design with rigorous internal validity. Limitations include the potential placebo effects, single-center setting, and small sample size. We expect taVNS to alleviate semaglutide-induced GI side effects and potentially enhance its therapeutic efficacy. In conclusion, this trial will provide preliminary evidence on the safety and effectiveness of taVNS as an supplementary therapy to semaglutide in T2DM, informing the design of future larger-scale studies.
Keywords: Transcutaneous auricular vagus nerve stimulation, Semaglutide, randomized controlledtrial, side effects, type 2 diabetes mellitus, Gastrointestinal side effects
Received: 27 Jun 2025; Accepted: 16 Oct 2025.
Copyright: © 2025 Tian, Zhang, Zhang, Ge, Luo, Zhang, Wang and Zhai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xu Zhai, zhaixu@mail.cintcm.ac.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.